Results 1 to 10 of about 34,457 (216)
Fibrinolytic agents for peripheral arterial occlusion. [PDF]
Cochrane Database Syst Rev, 2013 Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis.
Robertson I, Kessel DO, Berridge DC.
europepmc +4 more sources
Combining antithrombotic and fibrinolytic agents: can it be done? [PDF]
Stroke, 2013 More than half of ischemic stroke patients who are treated with IV recombinant tissue-type plasminogen activator (rtPA) remain disabled at 3 months.1,2 The reasons are many. The IV rtPA rate of recanalizing occluded arteries is not as high as we would like, especially for large arterial occlusions, which are opened only 30% to 40% of the time.3–6 When ...
Khatri P, Mono ML.
europepmc +4 more sources
Enhanced Production of Fibrinolytic Enzyme from Pseudomonas aeruginosa by Optimization Media Components [PDF]
Journal of Applied Sciences and Nanotechnology, 2021 Fibrinolytic enzyme is factor that lysis fibrin clots. This fibrinolytic factor has prospective use to treat cardiovascular diseases, such as stroke and heart attack. Cardiovascular diseases attracted worldwide attention for their elevation morbidity and
Bilal Jasim, Entesar Ali
doaj +1 more source
Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells. [PDF]
, 2012 Mesothelial cells are critical in the pathogenesis of post-surgical intraabdominal adhesions as well as in the deterioration of the peritoneal membrane associated with long-term peritoneal dialysis.
Djafarzadeh, Roghieh +10 more
core +14 more sources
Marine Drugs, 2022 Cardiovascular diseases (CVDs) have emerged as a major threat to global health resulting in a decrease in life expectancy with respect to humans. Thrombosis is one of the foremost causes of CVDs, and it is characterized by the unwanted formation of ...
Noora Barzkar +2 more
doaj +1 more source
Borneo Journal of Pharmacy, 2023 In the entire world, cardiovascular diseases (CVDs) are the main cause of death. For the treatment of CVDs, microbial fibrinolytic enzymes are highly regarded as novel therapeutic candidates.
Rebhika Lusiana +2 more
doaj +1 more source
Plant-Derived Compounds and Extracts as Modulators of Plasmin Activity—A Review
Molecules, 2023 Functionality of the fibrinolytic system is based on activity of its central enzyme, plasmin, responsible for the removal of fibrin clots. Besides the hemostasis, fibrinolytic proteins are also involved in many other physiological and pathological ...
Joanna Kolodziejczyk-Czepas, Jan Czepas
doaj +1 more source
BIO Web of Conferences, 2020 Cardiovascular disease is among the largest contributors of premature mortality in the world caused by inflammation of blood vessels. The abnormalities provoke thrombus formation or thrombosis blocking blood vessels leading to strokes, heart attacks and ...
Fuad Hayatun +9 more
doaj +1 more source
Pharmaceutics, 2021 Cardiac disorders such as acute myocardial infarction, embolism and stroke are primarily attributed to excessive fibrin accumulation in the blood vessels, usually consequential in thrombosis.
Chhavi Sharma +2 more
doaj +1 more source
Microorganisms, 2022 Fibrinolytic enzymes are the most effective agents for the treatment of thrombotic diseases. In the present study, we purified and characterized an extracellular fibrinolytic serine metalloprotease (named Velefibrinase) that is produced by marine ...
Yuting Zhou +4 more
doaj +1 more source